Celltrion Pharm's annual sales last year set a record high.
Celltrion Pharm announced on the 17th that its annual sales amounted to approximately 477.8 billion won, with an operating profit of about 37.2 billion won. Sales increased by 22.9% compared to the same period last year, marking the highest performance ever.
Celltrion Pharm analyzed that it achieved growth by increasing the sales portion of key products and new products. Despite the increase in workforce and research and development (R&D) expenses, operating profit also grew.
The chemical institutional sector reported sales of 204.8 billion won, a 23% increase compared to the previous year. The main product, the liver remedy 'Godekse,' showed solid performance, and the antihypertensive drug 'Dilatrend' began substantial sales last year, driving growth.
The biosimilar institutional sector also achieved sales growth of 18.2%, recording about 86.6 billion won. The autoimmune disease treatment 'Remsima SC,' which switched from intravenous (IV) formulation to subcutaneous (SC), grew by 34.3% compared to the previous year and led to strong performance. The sales of the Remsima product line amounted to about 44 billion won. The autoimmune disease treatment 'Uplima' also grew by 77% compared to the previous year, recording 3.6 billion won.
The oncology sector saw sales of 'Herzuma' grow by 42% to approximately 21.3 billion won. 'Vegzelma' also generated sales of about 3.8 billion won.
In the contract manufacturing sector, the production of pre-filled syringes (PFS) grew by 265% compared to the same period last year, achieving sales of about 92.6 billion won. The expansion of production for SC product items supplied to global key markets was significant.
Celltrion Pharm plans to expand sales thanks to the growth of existing products and the market establishment of new products. The company aims to maximize production facilities and secure differentiated competitiveness through R&D investment.
A Celltrion Pharm official noted, 'Last year was a year focused on solidifying the foundation of our core products while accelerating the market expansion of new products,' and added, 'We will do our best to achieve a quantum jump through the innovative development of new biosimilar products and R&D.'